Study Of Nivolumab Alone Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

  • STATUS
    Recruiting
  • End date
    Jul 27, 2023
  • participants needed
    64
  • sponsor
    The Lymphoma Academic Research Organisation
Updated on 12 May 2021
Investigator
Chloé GOURC BERTHOD
Primary Contact
CH Sud Francilien de Corbeil (0.0 mi away) Contact
+67 other location
lymphoma
chemotherapy regimen
nivolumab
vinblastine
classical hodgkin lymphoma

Summary

This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and CT scan responses. :

  • In case of CMR according to Lugano Classification (Cheson et al.2014, PET-CT based response), patients will receive 18 additional cycles of Nivolumab, according to CT-based response at Cycle 12.
  • In case of Partial Metabolic Response (PMR) or No Metabolic Response(NMR), according to Lugano Classification (Cheson et al.2014, PET-CT based response) patients will receive 12 to 18 cycles of Nivolumab combined with Vinblastin according to CT-based response at Cycle 12.
  • In case of progressive disease, according to Lugano Classification (Cheson et al.2014, PET-CT scan based response) patients will be considered in treatment failure.

Details
Condition Hodgkin's Disease, Lymphoma, Coexisting Medical Conditions, hodgkin, hodgkin's lymphomas, hodgkin lymphomas, hodgkins lymphoma, hodgkin's lymphoma
Treatment Nivolumab, Vinblastin
Clinical Study IdentifierNCT03580408
SponsorThe Lymphoma Academic Research Organisation
Last Modified on12 May 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note